Evidence map›Paper›PMID 29702525›Full record

ArticleInvestigative radiology2018

Feasibility of Dynamic Contrast-Enhanced Magnetic Resonance Imaging Using Low-Dose Gadolinium: Comparative Performance With Standard Dose in Prostate Cancer Diagnosis.

Dianning He, Aritrick Chatterjee, Xiaobing Fan, Shiyang Wang, Scott Eggener, Ambereen Yousuf, Tatjana Antic, Aytekin Oto, Gregory S Karczmar

Abstract readComparative Study
In one paragraph

Article in Investigative radiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. New prostate MRI techniques and sequences.Abdominal radiology (New York) · 2020
    Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Dianning He
Aritrick ChatterjeeRadiology.
Xiaobing FanRadiology.
Shiyang WangRadiology.
Scott EggenerUrology, and.
Ambereen YousufRadiology.
Tatjana AnticPathology, The University of Chicago, Illinois.
Aytekin OtoRadiology.
Gregory S KarczmarRadiology.
University Radiology · USNortheastern University · CN

Funding

VIRAL ONCOLOGY CORE FACILITYP30CA014599 · NCI · UNIVERSITY OF CHICAGO · PI MARK W. LINGEN · 1985 to 2026
$122.1M
Quantitative MRI for Predicting Response of Breast Cancer to Neoadjuvant TherapyU01CA142565 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI KARCZMAR, GREGORY S., NANDA, RITA · 2010 to 2019
$4.5M
Breast Cancer Screening with Quantitative Ultra-Fast DCEMRI and Clinical Risk AssessmentR01CA218700 · NCI · UNIVERSITY OF CHICAGO · PI KARCZMAR, GREGORY S. · 2017 to 2021
$3.0M
Quantitative DCEMRI of Prostate Cancer Correlation with Gold StandardsR01CA172801 · NCI · UNIVERSITY OF CHICAGO · PI KARCZMAR, GREGORY S., OTO, AYTEKIN · 2013 to 2017
$2.3M
3T MRI Scanner for multidisciplinary imaging and image-guided therapyS10OD018448 · OD · UNIVERSITY OF CHICAGO · PI KARCZMAR, GREGORY S. · 2014 to 2014
$2.0M
MRI of Early Non-invasive Rodent Mammary CancersR01CA133490 · NCI · UNIVERSITY OF CHICAGO · PI KARCZMAR, GREGORY S. · 2011 to 2015
$1.6M
NCI NIH HHS P30 CA014599NCI NIH HHS R01 CA133490NCI NIH HHS R01 CA172801NCI NIH HHS R01 CA218700NCI NIH HHS U01 CA142565NIH HHS S10 OD018448
6 · The paper itself

Abstract

objectivesThis study investigates whether administration of low doses of gadolinium-based contrast agent (GBCA) for dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) can be as effective as a standard dose in distinguishing prostate cancer (PCa) from benign tissue. In addition, we evaluated the combination of kinetic parameters from the low- and high-dose injection as a new diagnostic marker. MATERIALS AND

methodsPatients (n = 17) with histologically confirmed PCa underwent preoperative 3 T MRI. Dynamic contrast-enhanced MRI images were acquired at 8.3-second temporal resolution with a low dose (0.015 mmol/kg) and close to the standard dose (0.085 mmol/kg) of gadobentate dimeglumine bolus injections. Low-dose images were acquired for 3.5 minutes, followed by a 5-minute gap before acquiring standard dose images for 8.3 minutes. The data were analyzed qualitatively to investigate whether lesions could be detected based on early focal enhancement and quantitatively by fitting signal intensity as a function of time with an empirical mathematical model to obtain a maximum enhancement projection (MEP) and signal enhancement rate (α).

resultsBoth low- and standard-dose DCE-MRI showed similar sensitivity (13/26 = 50%) and lesion conspicuity score (4.0 ± 1.0 vs 4.2 ± 0.9; P = 0.317) for PCa diagnosis on qualitative analysis. Prostate cancer showed significantly increased α compared with benign tissue for low (9.98 ± 5.84 vs 5.12 ± 2.95 s) but not for standard (4.27 ± 2.20 vs 3.35 ± 1.48 s) dose. The ratio of low-dose α to standard-dose α was significantly greater (P = 0.02) for PCa (2.8 ± 2.3) than for normal prostate (1.6 ± 0.9), suggesting changes in water exchange and T2* effects associated with cancer. In addition, decreases in the percentage change in T1 relaxation rate as a function of increasing contrast media concentration (ie, the "saturation effect") can also contribute to the observed differences in high-dose and low-dose α. Area under the receiver operating characteristic curve for differentiating PCa from benign tissue using α was higher for low dose (0.769) compared with standard dose (0.625). There were no significant differences between MEP calculated for PCa and normal tissue at the low and standard doses. Moderate significant Pearson correlation for DCE parameters, MEP (r = 0.53) and α (r = 0.58), was found between low and standard doses of GBCA.

conclusionsThese preliminary results suggest that DCE-MRI with a low GBCA dose distinguishes PCa from benign prostate tissue more effectively than does the standard GBCA dose, based on signal enhancement rate. Diagnostic accuracy is similar on qualitative assessment. Prostate cancer diagnosis may be feasible with DCE-MRI with low-dose GBCA. In addition, comparison of enhancement kinetics after low and high doses of contrast media may provide diagnostically useful information.

Indexed as

AdultAgedContrast MediaFeasibility StudiesGadoliniumHumansImage EnhancementMagnetic Resonance ImagingMaleMiddle AgedProspective StudiesProstateProstatic NeoplasmsROC CurveContrast MediaGadolinium

Identifiers

PMID29702525
PMCPMC6512866
OpenAlexW2801038295

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.